Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service dialysis access cases in Wyoming: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 4% on average (245 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 1 | 127 | 5% |
| 2020 | 2 | 166 | 5% |
| 2021 | 3 | 145 | 6% |
| 2022 | 2 | 147 | 9% |
| 2023 | 2 | 98 | 15% |
| 2024 | 1 | 101 | 20% |
| 2025 from claims | – | 91 74–107 | 21% |
| 2026 forecast | – | 98 77–123 | 17% |
| 2027 forecast | – | 100 74–132 | 17% |
| 2028 forecast | – | 101 71–139 | 17% |
| 2029 forecast | – | 102 69–146 | 18% |
| 2030 forecast | – | 103 68–153 | 18% |
AV fistula and graft creation, access circuit angioplasty and stenting. Professional codes (what the surgeon bills): CPT 36821, 36830, 36902, 36903, 36905, 36906, 36818, 36819.
Since 2021 dialysis (ESRD) patients may join Medicare Advantage, and they have moved to it far faster than the county average, so fee-for-service decline here overstates the real one even after adjustment.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Wyoming; 1 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 100% hospital outpatient.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 204 | 20,282−7.2%/yr | −7.2%/yr | 6.3 | 68% | 20,800 in 2030+0.5%/yr |
| Arizona | 33 | 3,680−7.6%/yr | −7.6%/yr | 5.2 | 88% | 4,140 in 2030+2%/yr |
| Nevada | 20 | 2,124−8.8%/yr | −8.8%/yr | 7.7 | 96% | 2,190 in 2030+0.5%/yr |
| Washington | 30 | 2,051−12%/yr | −12%/yr | 2.8 | 19% | 1,780 in 2030−2.4%/yr |
| Colorado | 23 | 1,386−15%/yr | −15%/yr | 3.0 | 39% | 1,300 in 2030−1.1%/yr |
| Oregon | 16 | 1,041−9.9%/yr | −9.9%/yr | 2.6 | 56% | 1,090 in 2030+0.7%/yr |
| New Mexico | 7 | 658−16%/yr | −16%/yr | 3.0 | 83% | 1,090 in 2030+8.7%/yr |
| Utah | 9 | 647−6.1%/yr | −6.1%/yr | 3.1 | 40% | 580 in 2030−1.7%/yr |
| Hawaii | 8 | 567−14%/yr | −14%/yr | 4.6 | 62% | 560 in 2030−0.1%/yr |
| Idaho | 7 | 518−3.1%/yr | −3.1%/yr | 2.6 | 0% | 510 in 2030−0.2%/yr |
| Alaska | 8 | 491+1.8%/yr | +1.8%/yr | 4.1 | 49% | 400 in 2030−3.2%/yr |
| Montana | 1 | 182−11%/yr | −11%/yr | 1.0 | 0% | 260 in 2030+6.4%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Superficial venous ablation | 4 | 425−3.4%/yr | −3.4%/yr | 3.80.7× | 100% | 570 in 2030+4.9%/yr |
| Peripheral arterial intervention | 1 | 176+0.3%/yr | +0.3%/yr | 1.60.3× | 0% | 200 in 2030+2%/yr |
Dialysis access in every state, and its device makers · Every procedure market in Wyoming · Every state · Compare with California
No company payments named for these products in Wyoming in 2025.
FDA, last 12 months: 1 clearance or approval in the category, 2 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.